Dr Reddy’s Eyes Generic Revlimid Exclusivity With ANDA Approval
Follows Natco ANDA Approval Earlier This Year; Market To Form In Months
With Natco poised to debut the first batch of Revlimid generics in the US in March next year, fellow Indian ANDA sponsor Dr Reddy’s Laboratories has secured its own approval from the FDA for two strengths of the blockbuster multiple myeloma treatment.
